Nevertheless, targeting NOX2 appears promising, particularly in FLT3-mutant AML, based on pre-clinical in vitro data available; however, ongoing efforts are required to assess if this will translate into a meaningful clinical benefit. Here, FLT3 is linked to acute myeloid leukemia.